Results 61 to 70 of about 1,726,957 (305)

Predictors of Colorectal Cancer Screening Adherence among Male Veterans [PDF]

, 2014
poster abstractColorectal cancer (CRC) is the second leading cause of cancer mortality. However, CRC risk can be decreased through regular CRC screening and removal of precancerous polyps during endoscopic screening tests.
Christy, Shannon M., Haggstrom, David A., Mosher, Catherine E., Rawl, Susan M., Van Antwerp, Leah R.   +4 more
core  

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source

Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society

Ca, 2018
In the United States, colorectal cancer (CRC) is the fourth most common cancer diagnosed among adults and the second leading cause of death from cancer.
Andrew M.D. Wolf, Elizabeth T. H. Fontham, T. Church, C. Flowers, Carmen E. Guerra, S. J. LaMonte, Ruth Etzioni, M. McKenna, K. Oeffinger, Y. Shih, L. Walter, Kimberly S. Andrews, O. Brawley, D. Brooks, S. Fedewa, Deana Manassaram-Baptiste, R. Siegel, R. Wender, Robert A. Smith   +18 more
semanticscholar   +1 more source

Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation [PDF]

, 2017
This is the final version of the article. Available from the publisher via the DOI in this record.BACKGROUND: Inherited mutations in deoxyribonucleic acid (DNA) mismatch repair (MMR) genes lead to an increased risk of colorectal cancer (CRC ...
Aarnio, Ahadova, Arends, Balmana, Barnetson, Barrow, Barrow, Barrow, Barzi, Boland, Bonadona, Bonis, Bouzourene, Bowel Cancer UK, Burn, Cairns, Caldes, Calvert, Cancer Research, Cancer Research UK, Cancer Research UK, Centre for Reviews and Dissemination, Chang, Chen, Colling, Commercial Medicines Unit, Curtis, Curtis, Cuzick, de Boer, Department of Health, Desouza, Dietmaier, Dineen, Dinh, Doble, Dolan, Domingo, Dove-Edwin, Drummond, East of Scotland Regional Genetic Service, Eccleston, Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, Evers, Fajobi, Ferrandina, Finan, Frayling, Färkkilä, Gallego, Gallego, Gallego, Gavin, George, Giardiello, Goker, Goldstein, Great Britain, Grosse, Haanstra, Hall, Hampel, Hampel, Hanly, Haraldsdottir, Haraldsdottir, Havrilesky, Hendriks, Hildebrandt, Hornbrook, Hung, Ibrahim, Janus, Jenkins, John, Joint Formulary Committee, Järvinen, Järvinen, Kalady, Kaur, Kempers, Kloor, Kuppermann, Labianca, Ladabaum, Ladabaum, Le, Lewin, Ligtenberg, Lijmer, Limburg, Lin, Longworth, Loughrey, Lynch, Maeda, Mecklin, Mhaidat, Mittmann, Moher, Morak, Mueller, Mulder, Munoz, Mvundura, Møller, Møller, National Cancer Intelligence Network, National Cancer Intelligence Network, National Comprehensive Cancer Network, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, Ness, Newton, NHS, NHS Prescription Services, Niessen, Niv, Nout, Office for National Statistics, Office for National Statistics, Office for National Statistics, Office for National Statistics, Office for National Statistics, Office for National Statistics, Office for National Statistics, Office for National Statistics, Office for National Statistics, Office for National Statistics, Office for National Statistics, Office for National Statistics, Office for National Statistics, Office for National Statistics, Office for National Statistics, Office for National Statistics, Okkels, Overbeek, Overbeek, Palomaki, Pande, Parsons, Pawlik, Peninsula Technology Assessment Group (PenTAG), Philips, Pollett, Poulogiannis, Poynter, Ramsey, Ramsey, Ransohoff, Renkonen-Sinisalo, Sacco, Schmeler, Schnell, Senter, Severin, Sharp, Shia, Shlien, Sjursen, Sjursen, Slade, Snowsill, Snowsill, Southey, Stein, Sundar, The Stationery Office, Thompson, Thong, Trueman, UK Genetic Testing Network, Umar, US National Library of Medicine, Vasen, Vasen, Vasen, Vasen, Veysey, Wang, Ward, Webber, Welsh Cancer Intelligence and Surveillance Unit, Whiting, Whiting, Whiting, Wong, Wong, Wong, Zhang   +193 more
core   +2 more sources

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Decomposing socio-economic inequality in colorectal cancer screening uptake in England [PDF]

, 2015
Colorectal cancer (CRC) is the second largest cause of cancer death in the UK. Since 2010, CRC screening based on Faecal Occult Blood testing has been offered by the NHS in England biennially to all persons age 60-69 years.
Kobayashi, LC, Morris, S, Raine, R, Solmi, F, Von Wagner, C, Wardle, J   +5 more
core   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Appearances of screen-detected versus symptomatic colorectal cancers at CT colonography. [PDF]

, 2016
OBJECTIVES: The aim of this study was to compare the morphology, radiological stage, conspicuity, and computer-assisted detection (CAD) characteristics of colorectal cancers (CRC) detected by computed tomographic colonography (CTC) in screening and ...
Atkin, WS, Burling, D, Halligan, S, Nickerson, C, Pathiraja, F, Plumb, AA, Taylor, SA, Wooldrage, K   +7 more
core   +3 more sources

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source

A Multi-Level Fit-Based Quality Improvement Initiative to Improve Colorectal Cancer Screening in a Managed Care Population. [PDF]

, 2018
IntroductionColorectal cancer (CRC) is a common but largely preventable disease with suboptimal screening rates despite national guidelines to screen individuals age 50-75.
Betlachin, Anna, Esrailian, Eric, Garner, Omai B, Grossman, Mark, Hommes, Daniel W, May, Folasade P, Skootsky, Samuel, Yu, Christine   +7 more
core